EUCTR2004-004442-40-IT进行中（未招募）不适用
500 mcg roflumilast once daily in combination with 50 mcg salmeterol twice daily versus 50 mcg salmeterol twice daily alone over 52 weeks in patients with COPD. A double blind, parallel group, phase IIIb clinical study.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
500µg roflumilast once daily in combination with 50µg salmeterol twice daily versus 50µg salmeterol twice daily alone over 52 weeks in patients with COPD. - ROCKETEUCTR2004-004442-40-ESALTANA Pharma AG876
进行中（未招募）
不适用
500µg roflumilast once daily in combination with 50µg salmeterol twice daily versus 50µg salmeterol twice daily alone over 52 weeks in patients with COPD.COPDMedDRA version: 5.1Level: lltClassification code 10010952EUCTR2004-004442-40-ATALTANA Pharma AG955
进行中（未招募）
1 期
500µg roflumilast once daily in combination with 50µg salmeterol twice daily versus 50µg salmeterol twice daily alone over 52 weeks in patients with COPD.EUCTR2004-004442-40-GBALTANA Pharma AG100
进行中（未招募）
1 期
The trial investigates the effect of 500 µg roflumiliast tablets once daily on acute worsening of symptoms (exacerbations) treated with standard therapy in patiens with chronic obstructive pulmonary disease (COPD)Acute exacerbations of chronic obstructive pulmonary disease (COPD)MedDRA version: 16.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855MedDRA version: 16.0 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855EUCTR2011-002905-31-GBycomed GmbH81
进行中（未招募）
不适用
Efficacy of 500µg roflumilast once daily versus placebo over 12 weeks in patients with diabetes mellitus type 2. A double blind, parallel group, phase IIb, proof of concept clinical study - FORTUNAEUCTR2005-005702-23-DEycomed GmbH190